GLOBAL BLOOD THERAPEUTICS IN's ticker is GBT and the CUSIP is 37890U108. A total of 2 filers reported holding GLOBAL BLOOD THERAPEUTICS IN in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $2,522,000 | -86.9% | 37,029 | -93.8% | 0.00% | -75.0% |
| Q2 2022 | $19,234,000 | +1493.5% | 601,981 | +1626.8% | 0.00% | – |
| Q1 2022 | $1,207,000 | -2.0% | 34,861 | -17.2% | 0.00% | – |
| Q4 2021 | $1,232,000 | +17.6% | 42,106 | +2.4% | 0.00% | – |
| Q3 2021 | $1,048,000 | -97.9% | 41,136 | -97.1% | 0.00% | -100.0% |
| Q2 2021 | $50,245,000 | -28.5% | 1,434,727 | -16.8% | 0.01% | -33.3% |
| Q1 2021 | $70,258,000 | -20.4% | 1,724,128 | -15.4% | 0.01% | -25.0% |
| Q4 2020 | $88,270,000 | -29.1% | 2,038,120 | -9.7% | 0.02% | -38.5% |
| Q3 2020 | $124,517,000 | -18.0% | 2,258,195 | -6.1% | 0.03% | -23.5% |
| Q2 2020 | $151,830,000 | +7.5% | 2,405,050 | -13.0% | 0.03% | -8.1% |
| Q1 2020 | $141,227,000 | -38.6% | 2,764,264 | -4.5% | 0.04% | -22.9% |
| Q4 2019 | $230,082,000 | +24.7% | 2,894,485 | -23.9% | 0.05% | +14.3% |
| Q3 2019 | $184,442,000 | -1.3% | 3,801,362 | +7.0% | 0.04% | +2.4% |
| Q2 2019 | $186,904,000 | -2.0% | 3,553,294 | -1.4% | 0.04% | -4.7% |
| Q1 2019 | $190,669,000 | +25.8% | 3,602,270 | -2.5% | 0.04% | +13.2% |
| Q4 2018 | $151,625,000 | +3.9% | 3,693,688 | -3.8% | 0.04% | +22.6% |
| Q3 2018 | $145,916,000 | -19.6% | 3,839,910 | -4.4% | 0.03% | -22.5% |
| Q2 2018 | $181,543,000 | -13.4% | 4,016,423 | -7.5% | 0.04% | -14.9% |
| Q1 2018 | $209,679,000 | +150.5% | 4,341,191 | +104.1% | 0.05% | +161.1% |
| Q4 2017 | $83,688,000 | +9.2% | 2,126,767 | -13.8% | 0.02% | 0.0% |
| Q3 2017 | $76,631,000 | +19.3% | 2,467,993 | +5.1% | 0.02% | +20.0% |
| Q2 2017 | $64,242,000 | -24.9% | 2,348,856 | +1.2% | 0.02% | -28.6% |
| Q1 2017 | $85,534,000 | +182.5% | 2,321,123 | +10.8% | 0.02% | +162.5% |
| Q4 2016 | $30,275,000 | -39.3% | 2,095,129 | -3.3% | 0.01% | -38.5% |
| Q3 2016 | $49,915,000 | +85.7% | 2,165,511 | +33.7% | 0.01% | +85.7% |
| Q2 2016 | $26,877,000 | +301.0% | 1,620,046 | +283.4% | 0.01% | +250.0% |
| Q1 2016 | $6,702,000 | -79.3% | 422,556 | -57.8% | 0.00% | -75.0% |
| Q4 2015 | $32,346,000 | +14.1% | 1,000,502 | +45.9% | 0.01% | 0.0% |
| Q3 2015 | $28,339,000 | – | 685,714 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alerce Investment Management, L.P. | 356,270 | $24,262,000 | 23.36% |
| Twin Securities, Inc. | 376,669 | $25,651,000 | 11.94% |
| Paradigm Biocapital Advisors LP | 1,175,879 | $80,077,000 | 10.68% |
| Chicago Capital Management, LLC | 246,246 | $16,769,000 | 9.12% |
| HARVEST MANAGEMENT LLC | 141,500 | $9,636,000 | 7.78% |
| Fernwood Investment Management, LLC | 174,724 | $11,899,000 | 5.02% |
| ArchPoint Investors | 168,725 | $11,490,000 | 4.69% |
| HAVENS ADVISORS LLC | 46,000 | $3,133,000 | 4.69% |
| Perceptive Advisors | 2,322,247 | $158,145,000 | 4.59% |
| Crabel Capital Management, LLC | 112,680 | $7,674,000 | 4.48% |